Aims & Scope
Journal of Diseases publishes multidisciplinary research on the etiology, pathogenesis, diagnosis, treatment, and prevention of diseases across clinical, translational, and public health domains. We advance understanding from molecular mechanisms to population-level interventions.
Infectious Diseases Chronic Diseases Genetic Disorders Disease Mechanisms Clinical Trials Public Health Translational Medicine
Research Scope: Tiered Structure
Tier 1: Core DomainsInfectious Diseases
- Viral infections (HIV/AIDS, hepatitis, influenza, measles, mumps, Zika, Ebola, dengue, rabies)
- Bacterial diseases (tuberculosis, typhoid, plague, meningitis, diarrheal diseases)
- Parasitic diseases (malaria, babesiosis, gastrointestinal parasites)
- Zoonotic disease transmission and ecology
- Antimicrobial resistance mechanisms and surveillance
- Pathogenesis, pathogenicity, and host-pathogen interactions
Typical Fit: "Molecular characterization of drug-resistant tuberculosis strains in urban populations" or "Epidemiological modeling of dengue transmission dynamics in tropical regions"
Chronic & Non-Communicable Diseases
- Cardiovascular disorders (pathophysiology, risk factors, interventions)
- Metabolic diseases (diabetes, obesity-related complications)
- Cancer biology (oncogenesis, tumor microenvironment, biomarkers)
- Autoimmune diseases (mechanisms, diagnostics, therapeutics)
- Mental health disorders (neurobiological basis, treatment outcomes)
- Chronic respiratory and renal diseases
Typical Fit: "Novel biomarkers for early detection of diabetic nephropathy" or "Immunological profiling of rheumatoid arthritis patients undergoing biologic therapy"
Genetic & Rare Diseases
- Genetic disease mechanisms and molecular genetics
- Congenital disorders (etiology, prenatal diagnosis, management)
- Rare disease characterization and natural history studies
- Gene therapy approaches and outcomes
- Genomic medicine applications in disease diagnosis
- Idiopathic disease investigation and classification
Typical Fit: "Whole-exome sequencing identifies novel mutations in familial cardiomyopathy" or "Long-term outcomes of enzyme replacement therapy in lysosomal storage disorders"
Translational & Clinical Medicine
- Clinical trials (phase I-IV, novel therapeutics, comparative effectiveness)
- Diagnostic method development and validation
- Treatment strategies and patient management protocols
- Drug resistance mechanisms and therapeutic alternatives
- Biomarker discovery for prognosis and treatment response
- Translational studies bridging laboratory to clinical practice
Typical Fit: "Randomized controlled trial of combination therapy for refractory hypertension" or "Validation of point-of-care diagnostic for bacterial meningitis in resource-limited settings"
Epidemiology & Public Health
- Population-based disease surveillance and risk factor analysis
- Disease prevention interventions and health promotion strategies
- Environmental and social determinants of disease
- Outbreak investigation and epidemic modeling
- Health disparities and access to care studies
Disease Mechanisms & Pathology
- Molecular pathogenesis and cellular mechanisms
- Immunological responses in disease progression
- Pathophysiology of organ systems
- Disease biomarker identification and validation
- Comparative pathology across species
Microbiology & Parasitology
- Bacteriology, virology, and mycology in disease context
- Parasitology and entomology relevant to disease
- Opportunistic pathogens in immunocompromised hosts
- Microbial ecology and transmission dynamics
- Antifungal and antimicrobial development
Innovative Methodologies
- Artificial intelligence in disease diagnosis and prognosis
- Machine learning for treatment optimization
- Novel imaging techniques for disease detection
- High-throughput screening for drug discovery
- Omics approaches (genomics, proteomics, metabolomics)
Selective Consideration (Additional Editorial Review)
Precision Medicine: Personalized treatment strategies based on genetic, environmental, and lifestyle factors
Microbiome Research: Host-microbiome interactions in disease pathogenesis and therapeutic modulation
One Health Approaches: Integrated human-animal-environmental health perspectives on disease emergence
Digital Health: Telemedicine, mobile health applications, and wearable devices for disease monitoring
Regenerative Medicine: Stem cell therapies and tissue engineering for disease treatment
Immunotherapy: Novel immune-based approaches for cancer and autoimmune diseases
Note: Manuscripts in these areas undergo enhanced editorial screening to ensure strong disease focus and translational relevance. Purely methodological papers without clear disease application are typically declined.
Article Types & Editorial Priorities
Priority 1
Fast-Track Review
- Original Research Articles
- Systematic Reviews & Meta-Analyses
- Clinical Trials (all phases)
- Methods & Protocols
- Diagnostic Studies
Priority 2
Standard Review
- Short Communications
- Data Notes
- Perspectives & Commentaries
- Case Series (n≥5)
- Technical Notes
Rarely Considered
Selective Acceptance
- Single Case Reports (exceptional only)
- Opinion Pieces
- Letters to Editor
- Book Reviews
Editorial Standards & Requirements
Reporting Guidelines
All submissions must adhere to discipline-specific reporting standards:
- CONSORT for randomized controlled trials
- STROBE for observational studies
- PRISMA for systematic reviews
- ARRIVE for animal research (with human relevance)
- STARD for diagnostic accuracy studies
- CARE for case reports (when accepted)
Data Transparency
We require:
- Data availability statements for all research articles
- Deposition of genomic data in public repositories (GenBank, ENA)
- Clinical trial registration (ClinicalTrials.gov, ISRCTN)
- Sharing of protocols, code, and materials upon request
- Raw data for systematic reviews and meta-analyses
Ethics & Compliance
Mandatory documentation:
- IRB/Ethics committee approval for human studies
- Informed consent documentation
- IACUC approval for animal research
- Biosafety and biosecurity compliance
- Conflict of interest disclosures
- Funding source transparency
Preprint Policy
We welcome submissions that have been posted as preprints:
- Preprints on medRxiv, bioRxiv, or other recognized servers
- Authors must disclose preprint DOI at submission
- Preprint posting does not affect consideration
- Peer review remains independent of preprint feedback
Publication Metrics & Performance
21 Days Average Time to First Decision
70% Acceptance Rate (2024)
35 Days Average Time to Publication
Open Access Model (APC-based)
Ready to Submit?
If your research aligns with our scope and meets our editorial standards, we invite you to submit your manuscript for peer review.
Contact Editorial Office
